



Lyon and New York, July 9th 2015 - The MEDICREA group (Alternext Paris: FR0004178572 - ALMED, PEA-PME eligible), which specializes in the development and manufacturing of innovative surgical technologies for the treatment of spinal pathologies, today announced its sales for the 1st half of 2015.

FIRST-HALF SALES

| € millions | H1 2014 | H1 2015 | Δ |
|-------------------------|--------------|--------------|-------------|
| 1 st quarter | 5.40 | 5.80 | +7% |
| 2 nd quarter | 6.50 | 8.00 | +23% |
| TOTAL | 11.90 | 13.80 | +16% |

Variations in foreign exchange rates had a positive impact of 10% on H1 2015 sales.

The Group recorded total sales of 13.8 million euros in the 1st half of 2015, up 16% on the previous year and a new record high. The increase was driven in part by a particularly dynamic 2nd quarter (+23%) reflecting the first positive effects of the aggressive international strategy instigated in 2014 with the deployment of a new export sales team.

“MEDICREA is continuing to expand its distribution network in certain geographical regions, notably in Eastern Europe, Gulf states and Southeast Asia. We have also recently established a presence in Germany, Europe’s largest spine surgery market, thanks to the opening of MEDICREA GmbH, our new distribution subsidiary, on July 1st,” commented Denys SOURNAC, Chairman and CEO of MEDICREA.

In the United States, sales recorded during the 2nd quarter of 2015 by the MEDICREA USA Corp. integrated subsidiary reached a new high, with sales of 2.5 million dollars generated in June 2015 alone.

Next announcement: results for the 1st half of 2015 are expected to be released on September 9th 2015, after market

ABOUT MEDICREA (www.medicrea.com)

The MEDICREA Group specializes in the design, manufacture, and distribution of innovative proprietary technologies devoted exclusively to spinal surgery. Operating in a \$10 billion market, MEDICREA is a small to medium-sized business with 140 employees, including 40 at its MEDICREA USA Corp. subsidiary based in New York City.

The Company enjoys an excellent and ever-improving reputation, and develops unique scientific partnerships with some of the most visionary and creative spine surgeons in France, the UK, and the USA. The products developed and patented by MEDICREA provide neurosurgeons and orthopedic surgeons specializing in the spine with new and less-invasive surgical solutions that are faster and easier to implement than traditional techniques.

MEDICREA has also become **a pioneer and global leader** in the manufacturing of customized implants for personalized spinal surgery with the development of a comprehensive process incorporating the software analysis of each patient, the pre-surgical planning of the surgical strategy, and the production of customized spinal osteosynthesis rods (UNiD™ rod) and lumbar interbody osteosynthesis cages (UNiD™ ALIF cage) that are made to measure by a 3D printer.

The Group’s headquarters are based near Lyon, France. It also has an implant and surgical instrument manufacturing facility located in La Rochelle, France, as well as four distribution subsidiaries in the USA, the UK, France and Germany.

Contacts:

MEDICREA

Denys Sournac, Chairman and Chief Executive Officer
dsournac@medicrea.com
Tél : +33 (0)4 72 01 87 87

Fabrice Kilfiger, Chief Financial Officer
fkilfiger@medicrea.com
Tél : +33 (0)4 72 01 87 87

NewCap

Financial Communication / Press and Investor
Relations Sophie Boulila / Pierre Laurent
Tel: +33 (0)1 44 71 94 91
medicrea@newcap.fr

MEDICREA is listed on ALTERNEXT Paris
ISIN: FR 0004178572 – Ticker: ALMED

